Melan-A (MART-1) [A103], a melanoma-specific antigen, is a transmembrane protein and a melanocyte differentiation marker recognized by cytotoxic T lymphocytes. Melan-A is expressed in skin, in the majority of melanocytes and in renal angiomyolipomas (1-3). The Melan-A A103 clone, unlike clones M2-7C10 and M2-9E3, can also aid in the recognition of steroid hormone-producing tumors and may be particularly useful in the diagnosis of adrenocortical carcinoma (4,5).
1. Shidham VB, et al. Evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma: higher diagnostic accuracy with Melan-A and MART-1 compared with S-100 protein and HMB-45. Am J Surg Pathol. 2001 Aug;25(8):1039 -46.
2. Zubovits J, et al. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma. Hum Pathol. 2004 Feb; 35(2):217-23.
3. Tuna EB, Lebe B, Yörükoğlu K. HMB45 and melan-A expression in renal angiomyolipoma and their significance for the diagnosis. Tumori. 2003 Jan-Feb; 89 (1):46-8.
4. Busam KJ, et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol. 1998 Jan; 22(1):57-63.
5. Zhang HY, et al. [Diagnostic value of A103 and inhibin-alpha in adrenocortical tumors: an immunohistochemical study using tissue microarray techniques]. Zhonghua Bing Li Xue Za Zhi. 2004 Jun; 33(3):203-7.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.